ONCBeOne MedicinesNot started yet
Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 600 (planned)
- Started
- Oct 2026
- Main results expected
- Nov 30, 2029
- Fully finished
- Mar 31, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free survival (PFS) assessed by Blinded Independent Central Review (BICR)
Measured over: Up to 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07811271 · record last updated 2026-09-10 · checked 2026-11-09 15:47 UTC